Positron Corporation (POSC)

[was SaltLife]

ImaginAb, Inc. Concludes Licensing Agreement With UCLA for Novel Radiochemistry
Technology

LOS ANGELES, April 18, 2011 /PRNewswire via COMTEX/ -- ImaginAb, Inc. and the
University of California, Los Angeles (UCLA) have concluded a technology
licensing agreement relating to novel fluorine chemistry for the rapid and robust
labeling of proteins, peptides and biomolecules for diagnostic imaging with
Positron Emission Tomography (PET).

"We are pleased that ImaginAb has expanded its technology portfolio and
recognized the cutting-edge work being developed by the Crump Institute," said
Dr. Claire Wake, Director, at the university's Office of Intellectual Property
and Industry Sponsored Research (OIP-ISR).

"UCLA is truly a world leader in technologies related to PET, from Molecular and
Medical Pharmacology department chair Dr. Michael Phelps' pioneering of the field
some thirty years ago to the incredible multi-disciplinary innovation occurring
there today," said Dr. Christian Behrenbruch, CEO of ImaginAb. "This technology
will become an important part of ImaginAb's strategy to combine the readily
available and low-cost supply of F-18 from existing cyclotron networks with
ImaginAb's rapid development of targeted molecular imaging agents based on
antibody fragments and other small protein scaffolds."

The licensed technology originates from the UCLA's Crump Institute for Molecular
Imaging through research sponsored by the U.S. Department of Energy. The
agreement grants exclusivity to ImaginAb for antibodies and antibody fragments.

About ImaginAb

Founded in 2007 by UCLA faculty members Dr. Robert Reiter, Professor of Urology
and Molecular Biology, Dr. Anna Wu, Professor, Molecular & Medical Pharmacology
and then-faculty member Dr. Behrenbruch, ImaginAb, Inc. is a biotechnology
company specializing in the development of engineered antibody fragments for
diagnostic imaging and novel therapeutic applications. The company has a
significant pipeline of clinical products in development oriented towards unmet
needs in cancer and immunology. ImaginAb is also developing a range of
pre-clinical (animal imaging) reagents for use with microPET, microSPECT and
optical imaging systems, and partners on a selective basis with biopharmaceutical
companies with an interest in developing companion imaging agents for therapeutic
antibody products. For more information about ImaginAb, visit
http://www.imaginab.com.

Available Topic Expert(s): For information on the listed expert(s), click
appropriate link.Anna
Wuhttps://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=91513

SOURCE ImaginAb, Inc.

Copyright (C) 2011 PR Newswire. All rights reserved